Intra-Cellular Therapies Inc (ITCI) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas trimmed its holdings in Intra-Cellular Therapies Inc (NASDAQ:ITCI) by 34.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 9,628 shares of the biopharmaceutical company’s stock after selling 5,010 shares during the period. Teacher Retirement System of Texas’ holdings in Intra-Cellular Therapies were worth $203,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Renaissance Technologies LLC boosted its stake in Intra-Cellular Therapies by 43.3% in the 4th quarter. Renaissance Technologies LLC now owns 575,300 shares of the biopharmaceutical company’s stock worth $8,330,000 after buying an additional 173,700 shares during the last quarter. Millennium Management LLC boosted its stake in Intra-Cellular Therapies by 18.0% in the 4th quarter. Millennium Management LLC now owns 1,454,944 shares of the biopharmaceutical company’s stock worth $21,068,000 after buying an additional 221,980 shares during the last quarter. Deutsche Bank AG boosted its stake in Intra-Cellular Therapies by 16.4% in the 4th quarter. Deutsche Bank AG now owns 778,776 shares of the biopharmaceutical company’s stock worth $11,274,000 after buying an additional 109,636 shares during the last quarter. BlackRock Inc. boosted its stake in Intra-Cellular Therapies by 21.5% in the 4th quarter. BlackRock Inc. now owns 4,002,920 shares of the biopharmaceutical company’s stock worth $57,962,000 after buying an additional 709,048 shares during the last quarter. Finally, American International Group Inc. boosted its stake in Intra-Cellular Therapies by 26.3% in the 4th quarter. American International Group Inc. now owns 28,590 shares of the biopharmaceutical company’s stock worth $414,000 after buying an additional 5,955 shares during the last quarter. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

ITCI has been the topic of a number of research analyst reports. Cantor Fitzgerald reissued a “buy” rating and issued a $28.00 price target on shares of Intra-Cellular Therapies in a research note on Thursday, March 1st. Cowen reissued a “buy” rating and issued a $28.00 price target on shares of Intra-Cellular Therapies in a research note on Friday, March 2nd. SunTrust Banks reissued a “buy” rating and issued a $28.00 price target on shares of Intra-Cellular Therapies in a research note on Friday, March 2nd. Zacks Investment Research lowered Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research note on Tuesday, March 6th. Finally, Leerink Swann reissued an “outperform” rating on shares of Intra-Cellular Therapies in a research note on Sunday, March 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $28.27.

Intra-Cellular Therapies stock opened at $18.27 on Wednesday. The stock has a market capitalization of $1.01 billion, a PE ratio of -8.62 and a beta of 0.72. Intra-Cellular Therapies Inc has a 12 month low of $10.25 and a 12 month high of $25.82.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.01. Intra-Cellular Therapies had a negative return on equity of 27.67% and a negative net margin of 39,745.53%. equities research analysts anticipate that Intra-Cellular Therapies Inc will post -3.41 earnings per share for the current year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders.

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply